Shopping Cart
Remove All
Your shopping cart is currently empty
Sirtratumab vedotin (Synonyms: ASG-15ME, AGS15E, 1vcMMAE)
Catalog No. T9901A-021 Copy Product Info
Purity: 95%
🥰Excellent
Sirtratumab vedotin (ASG15-ME) is an ADC. Sirtratumab vedotin (ASG15-ME) conjugates a SLITRK6-specific human γ2 antibody (Igγ2) to the small-molecule microtubule-disrupting agent monomethylauristatin E (MMAE) via a protease-cleavable linker.
Sirtratumab vedotin
Copy Product Info🥰Excellent
Catalog No. T9901A-021
Synonyms ASG-15ME, AGS15E, 1vcMMAE
Sirtratumab vedotin (ASG15-ME) is an ADC. Sirtratumab vedotin (ASG15-ME) conjugates a SLITRK6-specific human γ2 antibody (Igγ2) to the small-molecule microtubule-disrupting agent monomethylauristatin E (MMAE) via a protease-cleavable linker.
Cas No. 1824663-83-3
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $718 | - | In Stock | |
| 5 mg | $1,790 | - | In Stock | |
| 10 mg | Preferential | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:95%
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Sirtratumab vedotin (ASG15-ME) is an ADC. Sirtratumab vedotin (ASG15-ME) conjugates a SLITRK6-specific human γ2 antibody (Igγ2) to the small-molecule microtubule-disrupting agent monomethylauristatin E (MMAE) via a protease-cleavable linker. |
| Targets&IC50 | SW780 cells:0.018 nM (Kd), CHP-212 cells:0.99 nM |
| In vitro | Sirtratumab vedotin (ASG15‑ME) binds with high affinity to SLITRK6 protein expressed on the surface of SW780 cells, with a Kd of 0.018 nM. After incubation at 10 μg/mL for 1 hour, sirtratumab vedotin binds to SLITRK6 and undergoes cellular internalization.Treatment for 120 hours significantly suppresses the viability of CHP‑212 cells, with an IC50 of 0.99 nM [1]. |
| In vivo | Sirtratumab vedotin (ASG15‑ME) demonstrates significant antitumor activity in multiple mouse xenograft tumor models. It is administered intravenously, with regimens including 0.25–5 mg/kg twice weekly for 2–3 weeks, or a single dose [1]. |
| Synonyms | ASG-15ME, AGS15E, 1vcMMAE |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal, ADC |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | MMAE |
| Gene ID | |
| Uniprot ID | |
| Target | SLITRK6 |
| Cas No. | 1824663-83-3 |
| Isotype | IgG1 |
| Storage | Store at -20°C Shipping with blue ice/Shipping at ambient temperature. |
Citations
Calculator
Preview
Related Tags: buy Sirtratumab vedotin | purchase Sirtratumab vedotin | Sirtratumab vedotin cost | order Sirtratumab vedotin | Sirtratumab vedotin chemical structure | Sirtratumab vedotin in vivo | Sirtratumab vedotin in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.